Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4700+0.0600 (+4.26%)
At close: 04:00PM EST
1.4300 -0.04 (-2.72%)
After hours: 07:57PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4100
Open1.3720
Bid1.4200 x 800
Ask1.4600 x 900
Day's Range1.3700 - 1.4899
52 Week Range1.3700 - 18.4940
Volume324,896
Avg. Volume896,909
Market Cap52.647M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.0260
Earnings DateNov 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • GlobeNewswire

    Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that on December 31, 2021, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 89,200 of the Company’s ordinary shares. The awards were granted as an ind

  • GlobeNewswire

    Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

    FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced th

  • GlobeNewswire

    Freeline To Participate In Conferences During January 2022

    LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to deliver a corporate presentation at both of the following virtual conferences: H.C. Wainwright BioConnect Conference, where an on-demand w

Advertisement
Advertisement